"...The European Commission has <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" />27 May 2009, after a long review by the European Medicines Agency (EMEA), decided to issue warnings about methylphenidate drugs. The Commission has also decided that a number of long-term studies of good quality should be done to investigate different harmful effects of these drugs. <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />
So for example the manufacturers were ordered to submit data how they could do long-term studies of psychiatric adverse effects (e.g. depression, hostility and psychotic reactions) and of cognitive effects (effects on learning, intellectual function) of the drugs. The answer from the pharmaceutical companies was a confidential report Feasibility Assessment of a Study of Long-term Effects of Methylphenidate on Cognition and Psychiatric Outcomes written 30 October 2009 now made public by a Swedish court.
As stated by the manufacturers: This information is provided on behalf of the following Marketing Authorisation Holders for methylphenidate-containing medicinal products in the EU: Novartis, Johnson & Johnson, Shire, Medice and Laboratorios Rubió (also referred to as the Consortium)...."